CellWell record HH-265258
Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science
Samantha Avila; Ingrid L Chen
2026
In plain language
Phase III trials found xanomeline-trospium significantly reduced PANSS scores versus placebo in adults with schizophrenia, with mainly mild gastrointestinal side effects and low discontinuation rates.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-265258
Produced by the CellWell Research Engine, custom software owned and operated by CellWell. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.